Telephos Intelligence — Qormi, MT

The behavioral measurement layer for neuroscience.

Objective, multimodal digital endpoints for CNS clinical research — and a predictive layer that quantifies and controls placebo response before Phase III.

For trial sponsors ↗For research partners ↗
420+
Participants across exploratory BPSD cohorts
5,144+
Clinician-administered, labeled assessments
2 patents
Pending — TSLVM
GB 2511888.6 · GB 2514969.1
§ 01 — Two products, one engine

One longitudinal behavioral
measurement engine.
Two ways pharma uses it.

Telephos captures multimodal patient–clinician interaction — facial micro-expressions, vocal prosody, head pose, physiology — and turns it into research-grade behavioral endpoints. The same engine powers two distinct offerings.

Door 1 — Endpoints platform

Behavioral endpoints for CNS research

A research-grade Digital Health Tool for capturing the full patient–clinician interaction across multi-site studies, and turning it into reproducible, quantitative endpoints. In use today in dementia-agitation cohorts; extending to psychosis and depression.

  • →Synchronized session video with speaker-attributed transcripts
  • →Objective behavioral signal from face, voice, and physiology
  • →Federated, multi-site by design — sites retain their data
  • →Reviewer dashboard for clinicians and study coordinators
Explore the platform →
Door 2 — AI-COPE

Predict placebo response. De-risk Phase III.

A live, per-patient score that quantifies placebo responsiveness — used as a pre-specified covariate to recover statistical power that placebo variance would otherwise erode.

  • →No new scales, no protocol disruption
  • →Works in any trial design, including decentralized
  • →FDA ISTAND qualification pathway in preparation
  • →Increases Phase III probability of success — and rNPV
How AI-COPE works →
§ 02 — At a glance

Built by people who've done this before.

1998
When our CSO began publishing on digital biomarkers

Ioannis Tarnanas, Founder of Altoida (FDA Breakthrough, 2021); adjunct professor at U-Michigan.

20y
CNS R&D leadership on the advisory board

Emilio Merlo-Pich (former Head of Neuroscience R&D, Takeda) as Fractional CMO.

Meet the full team →
§ 03 — Latest from us
§ perspective

Real-time clinical trials need a behavioral layer.

On the FDA's RTCT announcement, and where psychiatric endpoints fit.

The FDA's real-time clinical trial pilot is the right move at the right time. But structured EHR signals are not the endpoints that matter most in CNS and psychiatry — and the behavioral layer has to come along.

Read the full piece →
§ 04 — Get in touch

Three doors. Pick yours.

Sponsor inquiries about AI-COPE in upcoming trials. Investor conversations on the open Pre-Seed / Seed round. Research collaborations with academic and industry partners.